Disha Pharmaceutical Group Co., Ltd.

Disha Pharmaceutical Group Co., Ltd.

Disha Pharmaceutical Group Co., Ltd. was founded in 1993, with a registered capital of 599,770,627,000 yuan, located at No.1-4, Qingdao South Road, Weihai Economic and Technological Zone, covering an area of 442.32 acres. The company mainly produces Disha tablets (glipizide tablets), Diziya (candesartan ester tablets), Disu (cefaclor chewable tablets), Weitai (itopride hydrochloride dispersible tablets), and Lonar (losoprofen sodium tablets), which are used to treat various diseases, such as diabetes, hypertension. The sales network of the products has covered more than 90% of the provinces, cities and autonomous regions in China, and the market share of Disha Tablets (Glipizide Tablets) is about 30%.

The company has established long-term cooperation with Beijing University, Beijing University of Traditional Chinese Medicine, Shanghai Institute of Medical Science and Technology, Tianjin Institute of Medical Science and Technology and other colleges and research institutes. It has also signed a strategic cooperation agreement with Shanghai Institute of Pharmaceutical Research of the Chinese Academy of Sciences, Ocean University of China, and Jilin Academy of Traditional Chinese Medicine to set up a strategic cooperative relationship, and it has hired more than 30 domestic top experts and scholars as its R&D experts and consultants, such as academician Guan Huashi and academician Ding Jian.

The company has undertaken 10 national scientific research projects such as the National Torch Plan; 62 provincial scientific research projects such as major scientific and technological innovation projects in Shandong Province. It has obtained 39 valid invention patents in China. The company has set up a special position of Shandong Taishan Scholars in Pharmacy in 2010, and has been approved as the Academician's Workstation in Shandong Province in 2012, and has been recognized as the National Enterprise Technology Center in 2013, and has set up the National Post-doctoral Research Workstation in 2013, and has been approved as the National Post-doctoral Research Workstation in 2015. In 2015, the company was approved as Shandong Provincial Demonstration Engineering Technology Research Center for Endocrine Drugs.

In addition, the company has also obtained high level R&D platforms such as Shandong Marine Drugs and Functional Foods Research Center.